Immunoprecipitation: CEP350 Antibody [NB100-59811] - Detection of Human CAP350 on HeLa whole cell lysate using NB100-59811. CAP350 was also immunoprecipitated by rabbit anti-CAP350 antibody NB100-59810.
The immunogen recognized by this antibody maps to a region between residue 3066 and 3116 of human centrosome-associated protein 350 using the numbering given in entry NP_055625.3 (GeneID 9857).
Isotype
IgG
Clonality
Polyclonal
Host
Rabbit
Gene
CEP350
Purity
Immunogen affinity purified
Innovator's Reward
Test in a species/application not listed above to receive a full credit towards a future purchase.
This antibody is not recommended for crude preparations but can be used to blot CAP350 in enriched sources. ICC/IF, WB reactivity reported in (PMID: 20861314).
Theoretical MW
351 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
Publications
Read Publications using NB100-59811 in the following applications:
Canine reactivity reported in scientific literature (PMID: 25764135). Mouse reactivity reported in scientific literature (PMID: 28625565).
Packaging, Storage & Formulations
Storage
Store at 4C. Do not freeze.
Buffer
Tris-Citrate/Phosphate (pH 7.0 - 8.0)
Preservative
0.09% Sodium Azide
Concentration
1.0 mg/ml
Purity
Immunogen affinity purified
Alternate Names for CEP350 Antibody
CAP350GM133
centrosomal protein 350kDa
centrosome-associated protein 350
Centrosome-associated protein of 350 kDa
Cep350
FLJ38282
FLJ44058
KIAA0480centrosome associated protein 350
Background
CAP350 (Centrosome-Associated Protein 350) has been shown to localize to the centrosome as well as to dots in the pericentrosomal area. CAP350 functions to stabilize and anchor microtubules to the centrosome and participates in the maintenance of a pericentrosomal Golgi ribbon.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Tischer T, Yang J, Barford D Negative feedback between the APC/C and Cep152 at the centrosome regulates mitotic spindle assembly BioRxiv Jan 1 2020 (WB, Human)
WB
Human
Reviews for CEP350 Antibody (NB100-59811) (0)
There are no reviews for CEP350 Antibody (NB100-59811).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
Product General Protocols
Find general support by application which include: protocols, troubleshooting, illustrated assays, videos and webinars.
Bioinformatics Tool for CEP350 Antibody (NB100-59811)
Discover related pathways, diseases and genes to CEP350 Antibody (NB100-59811). Need help?
Read the Bioinformatics Tool Guide for instructions on using this tool.
Diseases for CEP350 Antibody (NB100-59811)
Discover more about diseases related to CEP350 Antibody (NB100-59811).
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our CEP350 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.